More information on the Antibody Engineering and Therapeutics Conference is available at. “We will continue to advance multiple programs through preclinical studies to the clinic, with a primary focus on cancer immunotherapy applications of our novel and proprietary IRC™ platform.” Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and Co-Founder. “Over the past year, Atreca has made substantial progress both in advancing our internal and partnered programs and attracting world-class experts to our leadership team and advisory group,” said Tito A. As our programs progress, we anticipate being able to advance these promising biologic agents for potential use in cancer immunotherapy, vaccines, and diverse additional therapeutic applications.” In one of our applications of IRC™, we generate natively paired antibody heavy and light chain sequences from blood plasmablasts – activated B cells – that are critical to the body’s own immune response to cancer and pathogens. Emerling stated, “Atreca’s IRC™ platform has demonstrated in preclinical disease models the power of mining a patient’s own anti-tumor immunity. In a presentation entitled “Analyzing B-cell Receptor Repertoires from Human Studies,” Daniel Emerling, Ph.D., Atreca’s Senior Vice President, Research, provided a summary of key findings from the Company’s preclinical programs, including:ĭr. ![]() ![]() ![]() REDWOOD CITY, Calif.-(BUSINESS WIRE)-Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today positive preclinical findings generated using the Company’s Immune Repertoire Capture® (IRC™) technology, presented at the IBC Antibody Engineering and Therapeutics Conference being held in San Diego, California, December 11-15, 2016.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |